Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
159.13
Nov 17 • 3:59 PM ET Dollar change-1.07 Percentage change(-0.67%)
Aftermarket Close
159.13
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Today, 6:25 AMNovartis received FDA approval for Cosentyx to treat adults with polymyalgia rheumatica, adding its 11th U.S. indication.
Index
-
Market Cap
291.30B
Enterprise Value
330.97B
Income
10.04B
Sales
55.35B
Book/sh
19.71
Cash/sh
4.90
Employees
75267
IPO
Nov 07, 1996
P/E
30.39
Forward P/E
16.10
PEG
2.50
P/S
5.26
P/B
8.07
P/C
32.46
P/FCF
18.62
EV/EBITDA
14.97
EV/Sales
5.98
Quick Ratio
0.70
Current Ratio
0.88
Debt/Eq
1.30
LT Debt/Eq
1.03
Option/Short
Yes / Yes
EPS (ttm)
5.24
EPS next Y
9.89
EPS next Q
2.25
EPS this Y
-0.76%
EPS next Y
10.94%
EPS next 5Y
6.45%
EPS past 3/5Y
31.40% 15.24%
Sales past 3/5Y
9.03% 2.29%
EPS Y/Y TTM
-28.72%
Sales Y/Y TTM
1.64%
EPS Q/Q
-68.95%
Sales Q/Q
4.03%
Insider Own
0.01%
Insider Trans
0.00%
Inst Own
7.40%
Inst Trans
7.71%
ROA
8.95%
ROE
24.62%
ROIC
13.28%
Gross Margin
74.30%
Oper. Margin
30.47%
Profit Margin
18.14%
SMA20
-0.16%
SMA50
6.39%
SMA200
4.23%
Trades
Shs Outstand
1.89B
Shs Float
1.83B
52W High
170.46 -6.65%
52W Low
123.24 29.12%
Volatility
1.16% 1.70%
ATR (14)
2.98
RSI (14)
55.01
Beta
0.41
Rel Volume
0.69
Avg Volume
2.11M
Volume
1,464,457
Perf Week
-2.53%
Perf Month
5.95%
Perf Quarter
-0.74%
Perf Half Y
5.78%
Perf YTD
15.42%
Perf Year
20.97%
Perf 3Y
67.66%
Perf 5Y
105.33%
Perf 10Y
158.82%
Prev Close
160.20
Price
159.13
Change %
-0.67%
Consensus
Buy
Avg. Price Target
$159.50
Implied Upside
+0.2%
Analysts12incl. previous ratings
Rating Distribution5 Buy · 5 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 30, 2026Downgrade
DB logoDDeutsche Bank
Hold → Sell
Sep 10, 2026Upgrade
HSBC logoHHSBC Securities
Reduce → Hold
Sep 09, 2026Initiated
RY logoRRBC Capital Mkts
Sector Perform
Sep 09, 2026Downgrade
DB logoDDeutsche Bank
Buy → Hold
Mar 11, 2026Upgrade
AArgus
Hold → Buy$180+13.1%
Jan 27, 2026Initiated
C logoCCitigroup
Buy
Jan 06, 2026Upgrade
BCS logoBBarclays
Underweight → Equal Weight
Dec 08, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight
Dec 03, 2025Upgrade
MS logoMMorgan Stanley
Equal-Weight → Overweight
Nov 25, 2025Upgrade
BAC logoBBofA Securities
Neutral → Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bulto Carulla VictorOfficerOct 28 '26Proposed Sale155.536,000933,180Oct 28 10:46 AM
Bulto Carulla VictorOfficerApr 30 '26Proposed Sale148.106,8001,007,093Apr 30 12:05 PM
Marshall FionaOfficerFeb 12 '26Proposed Sale161.3530,7434,960,277Feb 12 02:43 PM
Bulto Carulla VictorOfficerFeb 09 '26Proposed Sale156.217,5001,171,576Feb 09 11:49 AM
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Chief Executive OfficerDr. Vasant Narasimhan M.D.
President of USMr. Victor Bulto
President of InternationalDr. Patrick Horber M.D.
Chief Financial OfficerMr. Mukul Mehta
President of OperationsDr. Steffen Lang Ph.D.